KB002 is an engineered human IgG1k antibody engineered human. It is developed for the treatment of autoimmune diseases, initially rheumatoid arthritis.
- Mechanism
- Curator reviewed
KB002 is an engineered human monoclonal antibody. The drug targets and neutralizes the activity of granulocyte macrophage colony-stimulating factor, (GM-CSF), a pro-inflammatory cytokine/growth factor that stimulates the survival, proliferation, differentiation and function of several types of white blood cells, including the monocytes/macrophages that play a key role in the tissue damage associated with many autoimmune diseases.
- Primary indication
- Investigated for use/treatment in rheumatoid arthritis.Curator reviewed
- Code names
- KB002
Resolves to
What you can answer from here — as of April 02, 2025
Which drugs share a target with KB002, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account